- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
CannabCo Pharmaceutical Corp.
Low-Cost, Pharmaceutical-Grade Cannabis for Global Markets
This CannabCo Pharmaceutical Corp. profile is part of a paid investor education campaign.*
Overview
CannabCo Pharmaceutical Corp. is a Canadian-based full-service cannabis company with operations in Brampton, Ontario. The company has received its confirmation of readiness status from Health Canada to become a licensed producer and is currently building out its pilot facility in the Brampton area.
The company is dedicated to establishing itself as a leader in top quality affordable pharmaceutical grade Cannabis supply and cutting-edge research contributing to the growing needs of the Cannabis industry.
CannabCo will employ the most advanced cultivation, processing and packaging technologies with a focus on quality at reduced costs using Pharmaceutical methodology within a GMP environment.
CannabCo intends to use an enhanced technology known as PHOENIX for its cultivation initiatives, achieving high productivity and significantly lower cost at under $.50 per gram. The company intends to launch extraction initiatives as well as enter the oils, extracts and consumable markets upon completion of its 17,500-square-foot pilot facility. The facility is being built to EU GMP standards allowing access to the underserviced global pharmaceutical market.
CannabCo Company Highlights
- PHOENIX technology that can consistently produce pharmaceutical-grade cannabis at costs of under $.50 per gram indoors.
- 17,500-square-foot pilot facility is underway expected to produce 5,000 kilograms of cannabis annually.
- The expansion cultivation facility is expected to produce over 165,000 kilograms per annum.
- The company is at confirmation of readiness with Health Canada.
Interactive Chart
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.Â